Research
Hormonal
Retatrutide treatment for 48 weeks resulted in a least-squares mean percentage change in body weight of -24.2% in the 12 mg group compared to -2.1% in the placebo group.
Retatrutide may be an effective treatment option for significant weight loss in adults with obesity.
StrongSupportsmedium confidence
At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -24.2% in the 12-mg group, as compared with -2.1% in the placebo group.
Why this rating
Based on a phase 2, double-blind, randomized, placebo-controlled trial design.
Source
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Ania M. Jastreboff et al. · New England Journal of Medicine · 2023
rct · n=338Cited 940×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →